Google
BCTX — BRIACELL THERAPEUTICS CORP (Healthcare >> Biotechnology)
BCTX FAQ
What is BCTX's ROE?
BRIACELL THERAPEUTICS CORP reports a Return on Equity (ROE) of -124.86%.
What is BCTX's dividend yield?
BRIACELL THERAPEUTICS CORP offers a dividend yield of 0.00%.
What is BCTX's Deepscope Quality Score?
Deepscope rates BCTX's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy BCTX?
Deepscope's AI Timing Score for BCTX is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does BCTX belong to?
BRIACELL THERAPEUTICS CORP is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 3.09
Price
0.01
(0.32%)
Day Change
|
|
|---|
BCTX, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 43 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.09 |
| PBV / Sector |
0.89 / 4.75
GREAT
|
| Earning Per Share | -4.42 |
| PE / Sector |
N/A / 17.65
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
1.04 M
GREAT
|
| Average 1W Daily Value |
0.46 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
43% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-09 09:40:03 |
| Symbol | BCTX |
| Name | BRIACELL THERAPEUTICS CORP |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 8.70 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 26.80 / 9,000.42 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1
Phone: 604 921 1810
Website: https://briacell.com
Sector: Healthcare >> Biotechnology
Description: BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate theclinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
